Brokerages Set MaxCyte, Inc. (NASDAQ:MXCT) PT at $7.00

MaxCyte, Inc. (NASDAQ:MXCT) has earned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.00.

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday.

MaxCyte Stock Performance

Shares of MXCT stock opened at $0.81 on Thursday. MaxCyte has a twelve month low of $0.75 and a twelve month high of $4.49. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.52. The stock has a market capitalization of $86.19 million, a price-to-earnings ratio of -1.84 and a beta of 1.21.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The firm had revenue of $6.41 million during the quarter, compared to the consensus estimate of $8.37 million. Research analysts predict that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its holdings in MaxCyte by 7,935.4% in the second quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after purchasing an additional 11,665 shares in the last quarter. CWM LLC grew its position in shares of MaxCyte by 92.7% in the 2nd quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after buying an additional 5,836 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of MaxCyte during the 2nd quarter worth approximately $26,000. May Hill Capital LLC purchased a new stake in MaxCyte during the second quarter valued at approximately $27,000. Finally, State of Wyoming purchased a new stake in MaxCyte during the second quarter valued at approximately $38,000. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.